Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART27.13 in Cancer Anorexia and Weight Loss
2024-518177-33-00Phase 2Authorised
- Sponsor
- Artelo Biosciences
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised trial in cancer anorexia (not an established disease entity) comparing ART27.13 with Placebo (2 arms). Primary endpoints: Change in lean body mass, Change in anorexia and 1 more. Planned start Nov 2024; status: authorised.
02
Drugs
AZD-1940
03
Conditions
cancer anorexia (not an established disease entity)
Beyond the preview
Go deeper on 2024-518177-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518177-33-00.